Although hematologic cancers typically exhibit relatively low P-gp levels, post-treatment genetic instability, and clonal selection in refractory or relapsed patients enhance ABCB1 activation and P-gp overexpression. This evidence concerns the gene ABCB1 and hematopoietic and lymphoid cell neoplasm.